NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Efficacy and Safety of Ceftazidime-Avibactam (CAZ-AVI) in Chinese Participants With HAP (Including VAP)

CompletedPhase 4

Sponsor: Pfizer

Conditions: Hospital-Acquired Pneumonia

Interventions: Zavicefta, Ceftazidime-Avibactam

Countries: China

This is a prospective, single arm, open-label, multi-center clinical study evaluating the effectiveness and safety of CAZ-AVI in participants with HAP (including VAP), who have initiated treatment with CAZ-AVI in an inpatient hospital setting. The duration of antibiotic treatment with the CAZ-AVI is 7-14 days. Participants must receive intravenously (IV) CAZ-AVI in the hospital for at least 7 full days. There are no formal hypothesis tests planned for this study. The number and percent of participants having clinical cure, failure, and indeterminate at TOC visit in the cMITT analysis population will be summarized.

Eligibility overview

Sex: ALL

Age: 18 Years to 90 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Male or female participants ≥18 and ≤90 years of age.
* Onset of symptoms ≥48 hours after admission or \<7 days after discharge from an inpatient acute or chronic care facility.
* New or worsening infiltrate on chest X-ray obtained within 48 hours prior to screening.
* Participants have systemic signs and respiratory signs or symptoms of HAP/VAP

Exclusion Criteria:

* Other medical or psychiatric condition may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
* Participant is expected to require a treatment course for HAP longer than 14 days.
* The total duration of antibiotic exposure for antibiotics whose administration begins in the 48 hours is longer than 24 hours.
* Previous administration with an investigational drug within 30 days or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).
* Acute Physiology and Chronic Health Evaluation (APACHE) II score \>30 or \<10 using the most recent available data.

Locations (56)

Fuyang, Anhui, China
Beijing, Beijing Municipality, China
Fuzhou, Fujian, China
Xiamen, Fujian, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Guangzhou, Guangdong, China
Huizhou, Guangdong, China
Qingyuan, Guangdong, China
Shenzhen, Guangdong, China
Shenzhen, Guangdong, China
Zhanjiang, Guangdong, China
Zhanjiang, Guangdong, China
Nanning, Guangxi, China
Zunyi, Guizhou, China
Haikou, Hainan, China
Sanya, Hainan, China
Baoding, Hebei, China
Luoyang, Henan, China
Nanyang, Henan, China
Nanyang, Henan, China
Zhengzhou, Henan, China
Shiyan, Hubei, China
Wuhan, Hubei, China
Wuhan, Hubei, China
Changsha, Hunan, China
Yueyang, Hunan, China
Baotou, Inner Mongolia, China
Baotou, Inner Mongolia, China
Huai'an, Jiangsu, China
+ 26 more on CT.gov